Pharma News

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL, single-dose prefilled syringes.

Senores Pharmaceuticals Limited through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has signed agreement today to acquire the USFDA-approved Abbreviated New Drug Application for Topiramate HCl 25, 50, 100 and 200 mg tablets Topiramate from Wockhardt Limited.

Higher intakes of black tea, berries, citrus fruits and apples could help to promote healthy ageing, new research has found. This study conducted by researchers from Edith Cowan University, Queen's University Belfast and Harvard T.H. Chan School of Public Health, found that foods rich in flavonoids could help to lower the risk of key components of unhealthy ageing, including frailty, impaired physical function and poor mental health.

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests that artificial intelligence (AI) could help detect interval breast cancers — those that develop between routine screenings — before they become more advanced and harder to treat. This could potentially lead to better screening practices, earlier treatment and improved patient outcomes.

By using antibodies from a human donor with a self-induced hyper-immunity to snake venom, scientists have developed the most broadly effective antivenom to date, which is protective against the likes of the black mamba, king cobra, and tiger snakes in mouse trials.

Biocon Biologics Ltd , a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access agreements for Yesintek™, its biosimilar to Stelara®. The market access agreements from numerous plans represent over 100+ million lives in the United States.

Novartis announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus’ lead asset, farabursen.

Researchers have uncovered multiple new genes and genetic pathways that could lead to repurposing hundreds of existing drugs for osteoarthritis, the most common form of arthritis. The research, which analyzed data from nearly 2 million people in diverse populations worldwide, was recently published in Nature. It represents an extensive genetic exploration of osteoarthritis, a condition affecting over 600 million people globally.